BRISTOL GATIFLOXACIN IS SLATED TO GO FROM IND TO NDA IN THREE YEARS; LOBUCAVIR ACTIVITY AGAINST HEPATITIS B GREATER THAN INTERFERON OR 3TC, FIRM MAINTAINS
Executive Summary
The speed from IND-to-NDA for Bristol-Myers Squibb's quinolone antibiotic gatifloxacin "will establish a new industry standard for antibiotic development," VP-Infectious Diseases Clinical Research Roger Echols, MD, declared during an R&D meeting for analysts Dec. 5 at Bristol's Princeton, N.J. facilities.